Metastatic Colorectal Cancer Clinical Trials

A listing of 20 Metastatic Colorectal Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Colorectal Cancer

1 - 12 of 20

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 20 active clinical trials seeking participants for Metastatic Colorectal Cancer research studies. The states with the highest number of trials for Metastatic Colorectal Cancer participants are California, Florida, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481

Recruiting

Background: Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and spread to other organs. This is called metastatic colorectal cancer (mCRC). Most people with mCRC survive only about 2 years. Objective: To test the ability of a combination of up to 4 experimental anti-cancer drugs treat mCRC. The names of these drugs are retifanlimab, TriAdeno vaccine, N-803, and SX-682. They are described below. Eligi... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer

Learn More ›

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121

Recruiting

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause digestive tract, urothelial, breast, or ovarian/endometrial tumors to shrink and to see if this treatment is safe. Eligibility: - Adults age 18-72 with upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial cancer, or glioblastoma refractory to standard chemotherapy. Design: Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed. Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. (Leukapheresis is a common procedure, which removes only the white blood cells from the patient.) Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days. ... Read Less

Gender:

ALL

Ages:

Between 18 years and 72 years

Trial Updated:

05/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors

Learn More ›

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649

Recruiting

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/07/2025

Locations: Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona +214 locations

Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona

Providence Saint Jude Medical Center, Fullerton, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

California Research Institute, Los Angeles, California

Norwalk Hospital, Norwalk, Connecticut

Cancer Specialists of North Florida, Jacksonville, Florida

D and H Cancer Research Center, Margate, Florida

Mid Florida Hematology and Oncology Centers PA, Orange City, Florida

Boca Raton Clinical Research Medical Center Inc, Plantation, Florida

Georgia Cancer Specialists, Atlanta, Georgia

Hope and Healing Cancer Services, Hinsdale, Illinois

Orchard Healthcare Research Inc, Skokie, Illinois

Pikeville Medical Center, Pikeville, Kentucky

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan

Saint Louis Cancer Care West County, Bridgeton, Missouri

Minniti Center for Medical Oncology and Hematology, Mickleton, New Jersey

Duke Cancer Center, Durham, North Carolina

FirstHealth Cancer Center, Pinehurst, North Carolina

Thomas Jefferson University, Philadelphia, Pennsylvania

Carolina Blood and Cancer Care, Rock Hill, South Carolina

Hospital Universitario Fundacion Favaloro, Caba, Buenos Aires

Instituto Argentino de Diagnóstico y Tratamiento, Caba, Buenos Aires

Investigaciones Clinicas Moleculares - Centro de Endocrinologia y Diabetes Dr Raul Gutman SRL, Caba, Buenos Aires

Cemic, Ciudad Autonoma de Buenos Aires, Buenos Aires

Sanatorio Británico de Rosario, La Plata, Buenos Aires

Instituto de Investigaciones clinicas de Mar del Plata, Mar Del Plata, Buenos Aires

Hospital Italiano de Córdoba, Cordoba, Córdoba

Sanatorio Allende, Cordoba, Córdoba

Clinica Universitaria Privada Reina Fabiola, Cordoba, Córdoba

Clinica Viedma, Viedma, Río Negro

Exelsus Oncologia Clinica, San Miguel de Tucuman, Tucuman

Hospital Britanico de Buenos Aires, Buenos Aires, Not set

Centro Oncologico Riojano Integral, La Rioja, Not set

Chris OBrien Lifehouse, Camperdown, New South Wales

Toowoomba Hospital, Toowoomba, Queensland

Flinders Medical Centre, Bedford Park, South Australia

The Queen Elizabeth Hospital, Woodville South, South Australia

Austin Health, Austin Hospital, Heidelberg, Victoria

Ordensklinikum Linz Barmherzige Schwestern, Linz, Not set

Landeskrankenhaus Feldkirch, Rankweil, Not set

Institut Jules Bordet, Brussels, Not set

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Not set

Grand Hôpital de Charleroi - Site des Viviers, Charleroi, Not set

Universitair Ziekenhuis Gent, Gent, Not set

Algemeen Ziekenhuis Sint-Maarten, Mechelen, Not set

AZ Delta Campus Rumbeke, Roeselare, Not set

Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Not set

Hospital Sirio Libanes, Brasilia, Distrito Federal

Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Espírito Santo

Vencer e Oncoclinica, Teresina, Piauí

Liga Norte-Riograndense Contra O Cancer, Natal, Rio Grande Do Norte

Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul

Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul

Associação Hospitalar Moinhos de Vento, Porto Alegre, Rio Grande Do Sul

Clinica de Neoplasias Litoral, Itajai, Santa Catarina

Fundacao Pio 12 Hospital de Amor de Barretos, Barretos, São Paulo

Oncoclinicas Belo Horizonte, Barretos, São Paulo

Fundacao Antonio Prudente AC Camargo Cancer Center, Sao Paulo, São Paulo

Oncologia Rede D Or, Sao Paulo, São Paulo

Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo

Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, Not set

Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp, São Paulo, Not set

Instituto Brasileiro de Controle do Cancer Ibcc, São Paulo, Not set

Specialized Hospital for Active Treatment of Oncology - Haskovo EOOD, Haskovo, Not set

Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, Not set

Complex Oncology Center Plovdiv EOOD, Plovdiv, Not set

Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia, Sofia, Not set

Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, Not set

James Lind Centro de Investigacion del Cancer, Temuco, Cautín

Clinica Redsalud Vitacura, Instituto del Cancer, Vitacura, Santiago

Fundacion Arturo Lopez Perez, Santiago, Not set

Centro de oncologia de precision Spa, Santiago, Not set

Biocinetic, Santiago, Not set

Clinical Research Chile SpA, Valdivia, Not set

Institucion Prestadora de Servicios de Salud Sociedad Médica Rionegro SA Somer SA, Rionegro, Antioquia

Instituto Nacional de Cancerologia, Bogota, Cundinamarca

Centro de Tratamiento e Investigación sobre Cancer Luis Carlos Sarmiento Angulo Ctic, Bogotá, Cundinamarca

Instituto Medico de Alta Tecnologia sas - Imat sas, Montería, Córdoba

Fundacion Oftalmologica de Santander - Foscal, Floridablanca, Santander

Masarykuv onkologicky ustav, Brno, Not set

Fakultni nemocnice Olomouc, Olomouc, Not set

Fakultni nemocnice Kralovske Vinohrady, Praha 10, Not set

Fakultni nemocnice v Motole, Praha 5, Not set

Aalborg Sygehus, Aalborg, Not set

Aarhus University Hospital, Aarhus N, Not set

Rigshospitalet, Copenhagen, Not set

Odense University Hospital, Odense C, Not set

North Estonia Medical Centre Foundation, Tallinn, Not set

Centre Hospitalier Universitaire de Clermont Ferrand - Hopital Estaing, Clermont-Ferrand cedex 1, Not set

Hopital Henri Mondor, Creteil, Not set

Centre Hospitalier Universitaire de Dijon - Hopital du Bocage, Dijon Cedex, Not set

Institut regional du Cancer Montpellier, Montpellier Cedex 5, Not set

Hopital Saint Louis, Paris Cedex 10, Not set

Hopital Europeen Georges Pompidou, Paris, Not set

Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque, Pessac, Not set

Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, Not set

Hopital Robert Debre, Reims, Not set

Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou, Rennes Cedex 9, Not set

Centre Hospitalier Universitaire Nord de Saint Etienne - Hopital Nord, Saint Priest en Jarez, Not set

Institut de Cancerologie de l Ouest Rene Gauducheau, Saint-Herblain Cedex, Not set

Institut de Cancerologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy Cedex, Not set

Charite - Universitaetsmedizin Berlin, Campus Virchow, Berlin, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Universitaetsklinikum Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

UCT Universitaeres Zentrum fuer Tumorerkrankungen Frankfurt, Frankfurt am Main, Not set

Haematologisch Onkologische Praxis Eppendorf, Hamburg, Not set

Regional Kliniken Holding Klinikum Ludwigsburg, Ludwigsburg, Not set

Klinikum der LMU Muenchen, Muenchen, Not set

Universitaetsklinikum Ulm, Ulm, Not set

Klinikum der Stadt Wolfsburg, Wolfsburg, Not set

General Hospital Evangelismos, Athens, Not set

Agios Savvas Anticancer Hospital, Athens, Not set

Metropolitan Hospital, Athens, Not set

University Hospital of Larissa, Larissa, Not set

Bioclinic of Thessaloniki, Thessaloniki, Not set

Agios Loukas Clinic, Thessaloniki, Not set

Saint Lukes Hospital SA, Thessaloniki, Not set

European Interbalkan Medical Center, Thessaloniki, Not set

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Princess Margaret Hospital, Kowloon, Not set

Orszagos Onkologiai Intezet, Budapest, Not set

Debreceni Egyetem Klinikai Kozpont, Debrecen, Not set

Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Gyula, Not set

Somogy Varmegyei Kaposi Mor Oktato Korhaz, Kaposvar, Not set

Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaz, Nyiregyhaza, Not set

Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Not set

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Not set

Ente Ospedaliero IRCCS Saverio De Bellis, Castellana Grotte, Not set

Azienda Ospedaliero Universitaria Careggi, Firenze, Not set

Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, Foggia, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

Azienda Sanitaria Universitaria Friuli Centrale Presidio Ospedaliero Santa Maria della Misericordia, Udine, Not set

Azienda Ospedaliera Universitaria Integrata di Verona Ospedale Civile Maggiore Borgo Trento, Verona, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

Chiba Cancer Center, Chiba-shi, Chiba

National Cancer Center Hospital East, Kashiwa-shi, Chiba

National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime

National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka

Hokkaido University Hospital, Sapporo, Hokkaido

Hyogo Cancer Center, Akashi-shi, Hyogo

St Marianna University Hospital, Kawasaki-shi, Kanagawa

Yokohama City University Medical Center, Yokohama-shi, Kanagawa

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa

Niigata Cancer Center Hospital, Niigata-shi, Niigata

Kansai Medical University Hospital, Hirakata-shi, Osaka

National Hospital Organization Osaka National Hospital, Osaka-shi, Osaka

The University of Osaka Hospital, Suita-shi, Osaka

Saitama Cancer Center, Kitaadachi-gun, Saitama

Shizuoka Cancer Center, Sunto-gun, Shizuoka

Tokushima University Hospital, Tokushima-shi, Tokushima

National Cancer Center Hospital, Chuo-ku, Tokyo

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

National Cancer Center, Goyang-si Gyeonggi-do, Not set

Korea University Anam Hospital, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Centro Especializado en Investigacion y Tratamiento Oncologicos SC, Benito Juárez, Distrito Federal

Health Pharma Professional Research SA de CV, Mexico City, Distrito Federal

Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo León

Nederlands Kanker Instituut - Antoni van Leeuwenhoek, Amsterdam, Not set

Medisch Spectrum Twente, Enschede, Not set

Unidade de Saude Local de Almada-Seixal, EPE - Hospital Garcia de Orta, Almada, Not set

Unidade Local de Saude de Coimbra, EPE, Coimbra, Not set

Hospital Cuf Tejo, Lisboa, Not set

Hospital da Luz, SA, Lisboa, Not set

Unidade Local de Saude de Santa Maria, EPE - Hospital de Santa Maria, Lisboa, Not set

Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano, Matosinhos, Not set

Unidade Local de Saude de Entre Douro e Vouga, EPE - Hospital de Sao Sebastiao, Santa Maria da Feira, Not set

Institutul Clinic Fundeni, Bucharest, Not set

Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti, Bucuresti, Not set

Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, Cluj Napoca, Not set

Centrul de Oncologie Sf Nectarie SRL, Craiova, Not set

Institutul Regional de Oncologie Iasi, Iasi, Not set

SC Oncomed SRL, Timisoara, Not set

Hospital Universitario Reina Sofia, Cordoba, Andalucía

Hospital Universitario Virgen de las Nieves, Granada, Andalucía

Hospital Regional Universitario de Malaga, Malaga, Andalucía

Hospital Universitario Virgen del Rocio, Sevilla, Andalucía

Hospital Universitario Central de Asturias, Oviedo, Asturias

Hospital Universitario Marques de Valdecilla, Santander, Cantabria

Hospital Universitario de Burgos, Burgos, Castilla León

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña

Hospital General Universitario de Elche, Elche, Comunidad Valenciana

Hospital Clinico Universitario de Valencia, Valencia, Comunidad Valenciana

Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana

Hospital Universitario de Navarra, Pamplona, Navarra

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Södersjukhuset, onkologikliniken, Stockholm, Not set

Universitaetsspital Zuerich, Zuerich, Not set

China Medical University Hospital, Taichung, Not set

Taichung Veterans General Hospital, Taichung, Not set

Taipei Veterans General Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Not set

Siriraj Hospital, Bangkok, Not set

Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Not set

Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Not set

Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi, Ankara, Not set

Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Not set

Ankara Bilkent Sehir Hastanesi, Ankara, Not set

Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi, Edirne, Not set

Bezmialem Vakif Universitesi Hastanesi, Istanbul, Not set

Bagcilar Medipol Mega Universite Hastanesi, Istanbul, Not set

Acibadem Altunizade Hastanesi, Istanbul, Not set

Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Not set

Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi, Konya, Not set

Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya, Not set

Sarah Cannon Research Institute UK, London, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223

Recruiting

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +72 locations

UAB Comprehensive Cancer Center, Birmingham, Alabama

Mayo Clinic Arizona, Phoenix, Arizona

City of Hope Comprehensive Cancer Center, Duarte, California

cCare, Encinitas, California

USC Norris Cancer Center, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Stanford Cancer Center, Stanford, California

University of Colorado Cancer Center, Aurora, Colorado

Yale Cancer Center, New Haven, Connecticut

Eastern Ct Hema/Onco Assoc, Norwich, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

Moffitt Cancer Center, Tampa, Florida

Mary Bird Perkins Cancer Ctr, Baton Rouge, Louisiana

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

New York Cancer & Blood Specialists - Bronx, Bronx, New York

New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park, New York

New York Cancer and Blood Specialists-Central Park Hematology & Oncology, New York, New York

New York Cancer & Blood Specialists, Port Jefferson Station, New York

Duke University Medical Center, Durham, North Carolina

Hematology Oncology Salem, Salem, Oregon

UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Lumi Research, Kingwood, Texas

Swedish Cancer Inst., Seattle, Washington

Medical Oncology Associates, Spokane, Washington

Peter Maccallum Cancer Centre, Melbourne, Victoria

Princess Margaret Cancer Center, Toronto, Ontario

Jewish General Hospital, Montreal, Quebec

McGill University Health Center, Montreal, Quebec

Rigshospitalet, Onkologisk Klinik, København Ø, Not set

Charité Universitätsmedizin Berlin, Berlin, Not set

Katholisches Klinikum Bochum gGmbH - St. Josef-Hospital, Bochum, Not set

Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Dresden, Not set

Universitätsklinikum Düsseldorf, Düsseldorf, Not set

Asklepios Klinik Altona, Hamburg, Not set

SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III, Heilbronn, Not set

Klinikum der Universität München, Campus Großhadern, München, Not set

Universitätsklinikum Ulm, Ulm, Not set

Università degli Studi della Campania Luigi Vanvitelli, Napoli, Campania

Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio

Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia

Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia

IRCCS Istituto Oncologico Veneto (IOV), Padova, Veneto

National Cancer Center, Goyang-si, Not set

Chonnam National University Hwasun Hospital, Jeollanam-do, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Kraków, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Not set

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie, Warszawa, Not set

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Not set

START Madrid. Centro Integral Oncologico Clara Campal, Madrid, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei City, Not set

National Taiwan University Hospital, Zhongzheng Dist., Not set

Addenbrookes Hospital, Cambridge, Not set

Velindre Cancer Centre, Cardiff, Not set

Royal Free Hospital, London, Not set

Royal Marsden Hospital;Dept of Med-Onc, London, Not set

Sarah Cannon Research Institute, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)

NCT06625775

Recruiting

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/01/2025

Locations: University of California Los Angeles, Los Angeles, California +10 locations

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, HER2-Positive Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer

Learn More ›

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463

Recruiting

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: Yale New Haven Hospital /ID# 270565, New Haven, Connecticut +9 locations

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

NCT06412198

Recruiting

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations

Conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations

Learn More ›

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

NCT06553885

Recruiting

This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/21/2025

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Metastatic Colorectal Cancer, Hepatocellular Carcinoma

Learn More ›

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

NCT05854498

Recruiting

This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/16/2025

Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Conditions: Metastatic Colorectal Cancer

Learn More ›

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

NCT05985954

Recruiting

To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/30/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Metastatic Colorectal Cancer

Learn More ›

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

NCT04587128

Recruiting

The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an alternative treatment strategy to maximize the benefit to inhibition of epidermal growth factor receptor (EGFR) for a highly selected patient population. It will enroll 71 participants with left-sided, unresectable metastatic CRC. Participants will be on study up to 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/24/2025

Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Conditions: Metastatic Colorectal Cancer

Learn More ›

Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064

Recruiting

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to ant... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/24/2025

Locations: University of California, Los Angeles, Los Angeles, California +2 locations

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer

Learn More ›

1 - 12 of 20